Treatment

Metformin Improves Outcomes in Patients With Diabetes and Hepatitis C Cirrhosis

07/30/2015

Patients with type 2 diabetes who also have liver cirrhosis associated with hepatitis C virus (HCV) infection fare significantly better when they’re treated with metformin, results of a French study indicate. “We found that metformin treatment was independently associated with a decrease in HCC (hepatocellular carcinoma) occurrence and with a decreased rate of liver-related death,” the researchers report in the August issue of the Journal of Clinical Endocrinology and Metabolism. The authors point out that type 2 diabetes and hyperinsulinemia are common in patients with HCV cirrhosis, and that there’s evidence indicating that insulin resistance plays a role in the development of liver cancer. Therefore, treatment with metformin could be beneficial in this setting. To investigate, Dr. Emmanuel Cosson, with Hopital Jean Verdier in Bondy and Paris-Nord University, and colleagues studied a prospective cohort of 100 consecutive patients with ongoing HCV cirrhosis and type 2 diabetes, 26 of whom were treated with metformin. During follow-up for a median of 5.7 years, 39 patients developed HCC and 33 either died of liver-related causes or underwent a liver transplant, according to the report. The team found that the 5-year rate of HCC was 9.5% among the group receiving metformin compared with 31.2% in those who did not. On multivariate analysis, metformin was independently associated with reduced risk of HCC (hazard ratio 0.19, p=0.023). Similarly, the corresponding rate of death or transplantation was 5.9% vs 17.4% in the two groups, respectively. This translated to an adjusted hazard ratio for death/transplantation of 0.22 (p=0.049), Dr. Cosson and colleagues report. They note that this was an observational study, so cause and effect cannot be determined. “However,” they conclude, “our findings add to the increasing body of evidence and may justify the initiation of clinical trials evaluating metformin in patients with hyperinsulinemia and HCV cirrhosis.”

Reference: 

 

For more videos, visit our partners at The Doctor's Channel.

Related Content

Gastroenterology
Gastroenterology
Tight control and treat to target: How to assess the effectiveness of therapy
08/01/2018
08/01/2018
Atopic Dermatitis
brett a king dermatology
Atopic Dermatitis
Brett A. King, MD, PhD, on JAKi for Alopecia Areata in Adolescents
08/10/2017
In this video, Dr Brett A King from Yale School of Medicine talks about use of janus kinase inhibitors (JAKi) for the treatment of alopecia areata in adolescents.
08/10/2017
Diabetes
Diabetes
Anne Peters, MD, on Using Medical Devices for Monitoring Type 2 Diabetes
07/15/2021
In this video, Anne Peters, MD, discusses using diabetes devices, including using an A1C test and continuous glucose monitoring systems. She also spoke about this topic at our Practical Updates in Primary...
07/15/2021
Public Health
Public Health
Michael Niederman, MD, on How I Practice Now: Inpatient vs Outpatient Management Challenges
12/17/2020
In this video, Pulmonology Consultant Advisory Board Member Michael Niederman, MD, from Weill Cornell Medical College, talks about the challenges that pulmonary and critical care physicians may...
12/17/2020
Inflammatory Bowel Disease
Inflammatory Bowel Disease
Walter Koltun, MD, on the Role of Diet in Ileal Pouch–Anal Anastomosis
03/03/2020
In this video, Walter Koltun, MD, from Penn State Health, discusses how a patient’s diet can influence outcomes of ileal pouch–anal anastomosis, and more.
03/03/2020